ABGENIX AND THE XENOMOUSE PDF

Abgenix has a unique method for generating antibodies useful in treating a number of diseases, including cancer. In early , the company’s cancer has. Abgenix developed XenoMouse technology to enable the rapid generation of high affinity, fully human antibody product candidates to. Abgenix, Inc. will become the sole owner of the XenoMouseâ„¢, a leading technology for generating fully human antibody drugs useful in.

Author: Nelkis Daihn
Country: Ecuador
Language: English (Spanish)
Genre: Music
Published (Last): 24 February 2008
Pages: 259
PDF File Size: 18.2 Mb
ePub File Size: 11.93 Mb
ISBN: 339-3-25580-873-4
Downloads: 33784
Price: Free* [*Free Regsitration Required]
Uploader: Kazisar

Statements made in this press release about Abgenix’s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive products, future capital requirements and the extent and breadth of Abgenix’s patent portfolio.

As therapeutic products, antibodies have several potential advantages over other therapies. For more information on Abgenix, visit the company’s Web site at www.

Abgenix and the Xenomouse | Roman Dmowski –

Statements made in this press release about Abgenix’s XenoMouse technology, product development activities and collaborative arrangements other than statements of historical fact, are forward looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials, the progress of research and product development programs, the regulatory approval process, competitive fhe, future capital requirements and the extent and breadth of Abgenix’s patent portfolio.

Please see Abgenix’s public filings with the Securities and Exchange Commission for information about risks that may affect Abgenix. In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials for graft-versus-host disease, psoriasis, rheumatoid arthritis, and cancer.

  KULTURSCHOCK VIETNAM PDF

Chiron will be responsible for product development, manufacturing, and marketing of any products developed through the collaboration. An expanding bubble in an extra dimension Uppsala University Rerouting nerves during amputation reduces phantom limb pain before it starts MediaSource Proportion of cancers associated with excess body weight varies considerably by abgeniz American Cancer Society Reducing drinking could help with smoking cessation, research finds Oregon State University View all latest news.

Abgenix to become sole owner of Xenomouse fully human antibody technology

JT also retains options to, or licenses on, several antigen targets it has previously nominated under the Xenotech structure.

Glick Porter Novelli The acquisition, expected to close by year-end, is contingent upon approval under the Hart-Scott-Rodino Antitrust Improvements Act of Fully human antibodies are desirable because they avoid the risk of rejection present with mouse or partial mouse antibodies.

Abgenix is a biopharmaceutical company that develops and intends to commercialize antibody therapies for the treatment of such conditions as transplant-related diseases, inflammatory and autoimmune disorders, cardiovascular disease, infectious diseases, and cancer.

In addition, Abgenix has multiple proprietary antibody product candidates under development internally, three of which are in human clinical trials.

Breaking News Smelling in tiny houses: Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology. Skip to main content Contact: Glick Porter Novelli Disclaimer: For example, our recently completed multi-product alliances with two leading genomics companies, Human Genome Sciences and CuraGen, will be facilitated by this transaction.

JT to relinquish certain option and license rights it is currently entitled to.

An expanding bubble in an extra dimension Uppsala University Rerouting nerves during amputation reduces phantom limb pain before it starts MediaSource Proportion of cancers associated with excess body weight varies considerably by state American Cancer Society Reducing drinking could help with smoking cessation, research finds Oregon State University View all latest news.

  BS EN 10027-1 PDF

The highly specific interaction between an antibody and its target may, for example, reduce unwanted side effects that may occur with other therapies.

For all antibody products generated using XenoMouse technology and developed by JT, JT will make license fee payments to Abgenix as well as royalty payments on any product sales. Please see Abgenix’s public filings with the Securities and Xemomouse Commission for information about risks that may affect Abgenix.

Abgenix and the XenoMouse

Abgenix also will provide JT with licenses to related technology. Antibodies are naturally occurring proteins that the body’s immune system uses to combat many diseases. Breaking News Smelling in tiny houses: Abgenix has collaborative arrangements with multiple pharmaceutical and biotechnology companies involving its XenoMouse technology.

Under a separate research collaboration agreement, Chiron may use XenoMouse to generate fully human monoclonal antibodies on up to four cancer targets. Abgenix developed XenoMouse xenomousd to enable the rapid generation of high affinity, fully human antibody product candidates to essentially any disease target appropriate for antibody therapy.

This te also represents the eighth new potential product candidate being pursued by one of our XenoMouse collaborators this year. Abgenix also collaborates with the U.

Army Medical Research Institute of Infectious Diseases in which the Army uses the XenoMouse technology to make fully human antibodies that will be tested for their ability to provide protection against filovirus and poxvirus infections.

In return, Abgenix will receive a technology access payment and could receive additional fees and milestone payments plus royalties on future product sales by Chiron.

Filoviruses, such as Ebola virus and Marburg virus, and poxviruses, including smallpox, pose a potential biological warfare or bioterrorism threat.